Bruker Corporation · NASDAQ:BRKR

Bruker — Cowen 38th Annual Health Care Conference (March 2018)

15 slides from Bruker's conference presentation, Mar 12, 2018

  1. Slide 1: Bruker Corporation (NASDAQ: BRKR)

    Bruker Corporation (NASDAQ: BRKR) Bruker drives profitable growth by enabling scientific discoveries and delivering high-performance analytical, life science and diagnostic solutions. Innovation with Integrity © Bruker Corporation

  2. Slide 2: Safe Harbor Statement

    Bruker Corporation Safe Harbor Statement Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectati

  3. Slide 3: Bruker Overview

    Bruker Overview Differentiated Leader in Attractive Analytical, Life Science and Diagnostic Tools Markets BIOSPIN NANO Group Group • Founded in 1960, Bruker brand NMR/EPR for Life-Science & Atomic Force Microscopy stands for innovation. Fluorescence Microscopy for Cell Pharma Research Biology & Neur

  4. Slide 4: Core Strategies

    Bruker Core Strategies Portfolio initiatives and cost optimization drive profitable growth Bruker creates shareholder value by: Profitable  Being well-positioned in attractive life Growth science tools & diagnostic markets  Transforming our portfolio with a focus on six key high-growth, high-margi

  5. Slide 5: Portfolio Transformation

    Portfolio Transformation Portfolio Fundamentally reshaping the portfolio for faster growth & continued multi-year margin expansion Six Key High-Growth & High-Margin Initiatives: • Proteomics & Phenomics 2017 results: About 25% of • Biopharma & Applied Bruker’s revenue • Microbiology & Diagnostics Gr

  6. Slide 6: Progress towards Clinical Proteomics at US HUPO 2018

    Progress towards Clinical Proteomics at US HUPO 2018 Introducing an Integrated Clinical Proteomics Research Solution Bruker’s timsTOFTM Pro with PASEF and Evosep ONE fast nanoLC for high-throughput proteomics research:  timsTOF Pro: unique dual-TIMS-QTOF with trapped ion mobility separation (TIMS)

  7. Slide 7: Operational Excellence & Cost Optimization

    From Transformation and Rightsizing (2013-2016) Cost to Operational & Commercial Excellence (2017-2020) 2013 2014 2015 2016 2017 2018 2019 2020 Outsourcing Bruker BioSpin Rightsizing Operational Excellence & Cost Optimization Outsourcing • Product R&D Excellence Bruker NANO Rightsizing & Footprint C

  8. Slide 8: Key Objectives

    Bruker Key Objectives 1. Accelerate revenue growth:  Enhance our revenue growth rate over time with our portfolio transformation initiatives  Recent end market improvements in ACAD/GOV, Europe/US, global Industrial, Semi & Applied 2. Transform portfolio with focus on six high-growth, high-margin i

  9. Slide 9: FY 2018 Guidance

    FY 2018 Guidance: Sustained organic revenue growth, further operating margin expansion, solid non-GAAP EPS growth FY 2018 Guidance 2018 ASSUMPTIONS  Organic revenue growth: Revenue Growth y-o-y Approximately +7% approximately +3%  FX revenue tailwind: approximately +4% Non-GAAP Operating Margin +5

  10. Slide 10: www.bruker.com

    www.bruker.com © Bruker Corporation 10

  11. Slide 11: Reconciliation of GAAP to Non-GAAP Financial Measures

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (unaudited) (in millions, except per share amounts) Twelve Months Ended December 31, 2017 2016 Reconciliation of Non-GAAP Operating Income, Non-GAAP Profit Before Tax, Non-GAAP Net Income, and Non-GAAP EPS GAAP Operating Income

  12. Slide 12: Reconciliation of GAAP to Non-GAAP Financial Measures

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) (in millions, except per share amounts) Twelve Months Ended December 31, 2017 2016 Reconciliation of GAAP and Non-GAAP Gross Profit GAAP Gross Profit $ 813.0 $ 742.5 Non-GAAP Adjustments: Restructuring Costs 5.6 11.

  13. Slide 13: Reconciliation of GAAP to Non-GAAP Financial Measures

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) (in millions, except per share amounts) Twelve Months Ended December 31, 2017 2016 Reconciliation of GAAP and Non-GAAP Interest & Other Income (Expense), net GAAP Interest & Other Income (Expense), net $ (16.9) $ 0.

  14. Slide 14: Reconciliation of GAAP to Non-GAAP Financial Measures

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures (Unaudited) (in millions, except per share amounts) Twelve Months Ended December 31, 2017 2016 Reconciliation of GAAP Revenue and Non-GAAP Revenue GAAP Revenue as of Prior Comparable Period $ 1,611.3 $ 1,623.8 Non-GAAP Adjustme

  15. Slide 15: Reconciliation of GAAP to Non-GAAP Financial Measures

    Bruker Corporation Reconciliation of GAAP to NON-GAAP Financial Measures With respect to the Company's outlook for 2018 non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to such GA

Bruker — Cowen 38th Annual Health Care Conference (March 2018) on 6ix